[ A21-147] Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95
Last updated 06.01.2022
Project no.:
A21-147
Commission:
Commission awarded on 23.11.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Heart and circulation
Refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite appropriate restoration of volume and use of catecholamines or other available vasoconstrictive therapies
Unchanged after addendum:
Added benefit not proven.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-95 | Angiotensin II acetate (hypotension) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-01-06 A G-BA decision was published.